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Background: In Canada, there has been a disproportionate increase in adults with Class II (BMI 35.0–39.9 kg/m2) or
Class III obesity (BMI≥ 40 kg/m2) affecting 9 % of Canadians with increases projected. Individuals affected by severe
obesity (BMI≥ 35) are at increased risk of high blood pressure, cardiovascular disease, diabetes, cancer, impaired quality
of life, and premature mortality. Bariatric surgery is the most effective treatment for severe obesity. Laparoscopic
sleeve gastrectomy (LSG), a relatively new type of bariatric surgery, is growing in popularity as a treatment. The
global prevalence of LSG increased from 0 to 37.0 % between 2003 and 2013. In Canada and the US, between
2011 and 2013, the number of LSG surgeries increased by 244 % and LSG now comprises 43 % of all bariatric
surgeries. Since 2011, Eastern Health, the largest regional health authority in Newfoundland and Labrador (NL),
Canada has performed approximately 100 LSG surgeries annually.
Methods: A population-based prospective cohort study with pre and post surgical assessments at 1, 3, 6, 12, 18,
24 months and annually thereafter of patients undergoing LSG. This study will report on short - to mid-term
(2–4 years) outcomes. Patients (n = 200) followed by the Provincial Bariatric Surgery Program between 19 and 70 years of
age, with a BMI between 35.0 and 39.9 kg/m2 and an obesity-related comorbidity or with a BMI≥ 40 kg/m2 are enrolled.
The study is assessing the following outcomes: 1) complications of surgery including impact on nutritional status 2)
weight loss/regain 3) improvement/resolution of comorbid conditions and a reduction in prescribed medications 4)
patient reported outcomes using validated quality of life tools, and 5) impact of surgery on health services use and costs.
We hypothesize a low complication rate, a marked reduction in weight, improvement/resolution of comorbid conditions,
a reduction in related medications, improvement in quality of life, and a decrease in direct healthcare use and costs and
indirect costs compared to pre-surgery.
Discussion: Limited data on the impact of LSG as a stand-alone procedure on a number of outcomes exist. The findings
from this study will help to inform evidence-based practice, clinical decision-making, and the development of health
policy.
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Obesity, most often defined using body mass index or
BMI (kg/m2), is classified in categories that are reflective
of the increasing health risk associated with excess body
weight (Class I: BMI 30.0–34.9 kg/m2, Class II BMI
35.0–39.9 kg/m2, Class III BMI ≥ 40.0 kg/m2) [1, 2].
Severe obesity, herein defined as Class II and III, is asso-
ciated with much higher levels of morbidity, increased
demands on the health care system, and premature
death [3–5]. It increases the risks of developing high
blood pressure, cardiovascular disease and type 2
diabetes [3], significantly impairs quality of life [6], and
shortens life expectancy [5].
Over the last three decades, the prevalence of obesity
has increased in many countries [7]. In Canada, obesity
currently affects 25 % of adults with severe obesity increas-
ing over 400 % since 1985 and now affecting nearly 10 %
of the population or approximately 1,000,000 Canadians
[8, 9]. The estimated annual economic burden of obesity
evidenced by direct costs related to hospitalizations,
medication use, physician and emergency room visits,
and indirect costs related to reduced work productiv-
ity and increased absenteeism, is now estimated to be
between $4.6 billion and $7.1 billion [10, 11].
Bariatric surgery
Severe obesity is difficult to treat. Treatments that in-
clude changes in diet, exercise, behavioral modification/
counselling, medical management or pharmacotherapy
have demonstrated limited effectiveness as successful
treatments for weight loss or long-term weight control.
On average these interventions result in a modest weight
loss of 5–10 % of initial body weight [12–14].
Bariatric surgery, the most effective treatment for
those with severe obesity, offers significant and sustained
weight loss, improvement in comorbid conditions and
quality of life, and reduces the risk of death [15–23].
Canadian guidelines exist on the surgical treatment of
adult obesity. Surgery is indicated in medically refractory
patients with a BMI ≥ 35 kg/m2 plus obesity-related co-
morbidity condition (e.g., hypertension, diabetes) or a
BMI ≥ 40 kg/m2 [3].
There are several different types of bariatric surgery
and all involve an alteration of the digestive system in
either a restrictive, malabsorptive, or combination re-
strictive/malabsorptive capacity [3, 20–23]. Restrictive
type bariatric procedures impose a physical limitation on
the amount of food that can be consumed by reducing
gastric volume. The most common procedures include
(a) laparoscopic sleeve gastrectomy (LSG) where the
greater curvature and fundus of the stomach are surgi-
cally resected leaving an elongated tube or stomach
‘sleeve’ and (b) adjustable gastric banding (AGB) where
the proximal stomach is encircled with an adjustableband that is progressively inflated to create a small
restrictive gastric pouch. Malabsorptive procedures
restrict nutrient and calorie absorption in the small
intestine and include the biliopancreatic diversion/duo-
denal switch (BPD/DS). Other bariatric surgeries use a
combination of restriction and malabsorption to pro-
mote weight reduction, and of these the most com-
monly performed is the gold standard roux-en-y gastric
bypass (RYGB) which results in a highly restrictive
gastric pouch coupled with a diversion of the upper
small intestine [21].
In 2003, 146,301 bariatric procedures were performed
worldwide with the majority (103,000) performed in the
United States and Canada. The types of procedures com-
prised of 85 % RYGB, 9 % AGB, and 4.5 % BPD/DS [24].
Since 2003, a significant shift has occurred in the type of
procedure being performed. In 2013, the total number of
worldwide procedures increased to 468,609 (with 154,276
performed in US/Canada) and was comprised of 45.0 %
RYGB, 37.0 % LSG, 10.0 % AGB, and 1.5 % BPD/DS. Simi-
lar to the worldwide shift in type of procedure being per-
formed, in Canada and the US, between 2011 and 2013,
the number of LSG surgeries increased by 244 % and now
comprises 43 % of all bariatric surgeries [25].
These changes reflect the exponential growth of LSG
both worldwide and in the United States and Canada
[25]. Over 90 % of bariatric surgeries are performed
laparoscopically [21]. This minimally invasive approach
reduces surgical risk, hospital stay, and recovery time
compared to open techniques and has contributed to
the increasing popularity of this approach [26].
Bariatric surgery outcomes
A recently published systematic review and meta-analysis
by Chang et al. [27] on the effectiveness and risks of bar-
iatric surgery provides an update on studies published
between 2003 and 2012 comparing surgical and non-
surgical treatments for severe obesity. This review
includes 164 studies (n = 161,756): 37 randomized con-
trolled trials (RCT) and 127 observational studies (OBS).
Just over half of the studies, 54 % (n = 91), provided
follow-up data on patients for ≥ 2 years. The mean age
(years) and BMI (kg/m2) of patients was 44.6 and 45.6,
respectively and almost 80 % were women. Average pre-
surgery weight was 124.53 kg. About a quarter of the
patients had diabetes (26 %), dyslipidemia (27 %) and sleep
apnea (25 %), while almost half had hypertension (47 %).
The review reported on the three most common bariatric
procedures currently performed by type of study, RCT or
OBS. Average percent excess weight loss (%EWL) at
3 years was 57 % (RCTs) and 67 % (OBS). Remission of
comorbid conditions occurred in the majority of patients:
diabetes 92 % (RCT), 86 % (OBS); hypertension 75 %
(RCT), 74 % (OBS); dyslipidemia 76 % (RCT), 68 % (OBS);
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were 17 % (95 % CI 11–23 %) (RCT) and 10 % (95 % CI
7–13 %) (OBS) and reoperation rates were 7 % (95 % CI
3–12 %) (RCT) and 6 % (95 % CI 4–8 %) (OBS). In the
RCT group the 30-day mortality rate was 0.08 % (95 % CI
0.01–0.24) compared to 0.31 % (95 % CI 0.01–0.75 %) for
the OBS group.
Mortality
Compared to non-surgical treatments for obesity, bar-
iatric surgery is associated with a reduced risk of death
[16, 18, 28–30]. A recent meta-analysis reported that
bariatric surgery reduced the risk of mortality and car-
diovascular mortality when compared to non-surgical in-
terventions through a reduction in myocardial infarction,
diabetes, and cancer-related deaths [28]. A reduced risk of
mortality within 2–5 years of surgery has been reported in
Canadian (89 %) [18], Australian (72 %) [30] and US
(40 %) studies [29]. The Swedish Obesity Study (SOS) of
more than 2000 patients, age and sex matched with obese
controls, reported a 29 % reduction in mortality (adjusted
HR 0.71 95 % CI 0.54–0.92) at 16 years [16]. More recent
data from the SOS on 20 year mortality outcomes report
an even more significant reduction (HR 0.47 95 % CI
0.29–0.76) in cardiovascular death (including MI and
stroke) [31].
Quality of life
Health related quality of life (HRQoL) encompasses
measures of well-being and physical and psychosocial
functioning [32]. Severe obesity is associated with
significantly impaired HRQoL [32, 33]. In general,
HRQoL improves in patients after bariatric surgery
[19, 34–36]. However, findings are inconsistent [37],
and improvements may often be limited to physical
functioning with less improvement observed in emo-
tional or mental functioning [36]. In addition very
limited data on the long-term (>5 years) impact of
bariatric surgery on quality of life exists [38].
Complications
Data on complications suggest the benefits of bariatric
surgery outweigh the harms [26, 27]. Perioperative mortal-
ity is low (<0.3 %) and declining [38]. The incidence of
complications (e.g., pulmonary complications, vomiting,
wound infection, hemorrhage, anastomotic leak) in the
first 30–180 days after surgery varies widely from 4 to
25 % and depends on the definition of complication used,
type of procedure, duration of follow-up, and individual
patient characteristics. A study by Hutter et al. [39]
reviewed the complication rates of 22,365 cases (944 LSG,
14,491 LRYGB, 988 open RYGB, 12,193 LAGB) and found
that LSG fell below LRYGB but above LAGB for post-
operative rates of morbidity, mortality, readmission, andreoperation rates. Long-term, the rates of reoperation as a
result of complications, insufficient weight loss, or weight
regain are a concern [40]. The effect of LSG on acid reflux
is still controversial and requires further research [41].
Longer term there is some evidence that nutritional defi-
ciencies (e.g., calcium, vitamin D, iron, zinc) may develop
after bariatric surgery and the effect on bone health is
unknown and also requires further study [26].
Emerging data from observational studies suggest that
some bariatric procedures may increase the risk of sub-
stance misuse disorders (i.e., alcohol) and suicide [42].
Pharmacokinetic studies suggest that changes in the
gastrointestinal anatomy after gastric bypass and sleeve
gastrectomy may lead to a more rapid absorption of
alcohol and increases in blood alcohol concentrations
per dose, inadvertently increasing the frequency of
physiological binges and subsequent alcohol misuse dis-
order [42, 43]. The risk of suicide after bariatric surgery
may be increased but the cause is unclear [42]. The Utah
Mortality study among others has demonstrated a small
but significant increase in the number of suicides after
surgery [29]. In addition, there are anecdotal reports of
the development of addictive behaviors such as gam-
bling, shoplifting, and driven sexual behavior [43]. It
should be noted that these observations are limited due
to the paucity of data on long-term psychological assess-
ment in these patients.
Economic evaluation
Studies have reported that bariatric surgery, mainly
RYGB and AGB, are more cost-effective than non-
surgical care [21, 22, 44–46] due to sustained weight
reduction, decreased use of medications (especially for
diabetes and cardiovascular disease), reduced outpatient
and physician visits, and improved quality of life. How-
ever, the complexity of RYGB is associated with early
complications resulting in increased inpatient stays. As
well, the overall costs of AGB are increased due to reo-
perations and band removals [47]. Newer procedures,
such as LSG have the potential to yield increased cost
savings due to its relatively low complication rate and
early evidence that clinical outcomes such as weight loss
and comorbid resolution are comparable with RYGB
[48]. There has not been an economic evaluation of
LSG.
Laparoscopic sleeve gastrectomy as a treatment for severe
obesity
LSG began as the first stage of a two-tiered operation of
duodenal switch or RYGB for very large (e.g., BMI ≥
50 kg/m2) or high-risk patients [3, 22, 49, 50]. Sleeve
gastrectomy involves the surgical resection of the greater
curvature and fundus of the stomach which creates an
elongated tube or stomach ‘sleeve’ along the lesser
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ively restricting caloric intake and increasing feelings of
satiety. Removal of the fundus has also been associated
with endocrine and metabolic effects [21], for example,
the reduction of circulating levels of ghrelin – a hunger
hormone, which may reduce the desire for food. It is not
yet fully understood how LSG creates favorable metabolic
changes and weight loss but this topic is a major focus of
research. Since the early 2000’s, LSG grew in popularity as
a stand-alone bariatric surgery because of the perceived
technical ease of performing the surgery, associated
obesity-related comorbidity improvement or resolution,
and good short-term weight loss outcomes [25, 26]. It is
now recognized as a primary bariatric surgery option and
as a first-stage procedure in high-risk patients as part of a
planned staged approach [26]. In a recent systematic re-
view conducted by Victorzon in 2012, the author noted
that the quantity, quality, and consistency of evidence for
LSG for the treatment of obesity were low. Victorzon sug-
gested that although numerous short-term studies had
shown that LSG had good outcomes of between 45–60 %
EWL, no longer term studies with >100 patients have
been published [50]. For LSG, average clinically expected
%EWL has been reported to be 56.1 % within the first year
after surgery but there is limited data on sustained or con-
tinued weight loss longer term [51]. In a systematic review
[51] the maximum weight loss reportedly occurred at 24
and 36 months following LSG surgery with %EWL’s of
64.3 % (46.1–75.0 %) and 66.0 % (60.0–77.5 %), respect-
ively [51]. In a small study examining average %EWL
5 years following surgery %EWL was 86 % (50–103 %),
but only 49 patients had complete follow-up data [52].
In general, bariatric surgery is effective in the resolution
of many obesity-related medical comorbidities (e.g., type 2
diabetes mellitus [T2DM], hypertension, sleep apnea) [53],
although data comparing the impact of RYGB and LSG
on T2DM is inconsistent. A recent systematic review and
meta-analysis compared the gold standard RYGB to LSG
and found no significant difference in resolution of T2DM
at 3 years (81 vs. 80 %) [54], however, other studies have
shown inconsistent results when comparing the two pro-
cedures on improvements in glycemic control, achieving
glycated hemoglobin value, and remission [49, 55, 56]. In
contrast to T2DM, there does not appear to be a signifi-
cant difference between RYGB and LSG on other comor-
bid conditions including dyslipidemia and hypertension
[55, 57]. However, the development of reflux disease after
LSG has been reported [57, 58] but a recent systematic
review evaluating the effect of LSG on GERD reported
inconsistent outcomes [59].
Knowledge gaps
The prevalence of severe obesity has increased dramatic-
ally in Canada and bariatric surgery is currently the onlyeffective treatment option offered to medical refractory
patients. Identifying cost-effective strategies to treat
severe obesity must be a priority for governments and
healthcare systems as healthcare expenditures of severely
obese adults are double that of normal weight individ-
uals [60]. Since 2003, there has been an exponential
increase in the number of LSG’s performed as a treat-
ment for severe obesity. There is evidence to support the
efficacy of LSG in terms of weight loss and comorbid
improvement/resolution, however data on other out-
comes are limited (e.g., weight loss sustainability or
recidivism, comorbid regression, nutritional deficiencies,
non-alcoholic fatty liver disease [NAFLD], polycystic
ovary syndrome [PCOS], quality of life, health ser-
vices use and costs, short-term psychiatric problems),
especially when based on a sample size of at least
80 % with follow-up of 2 years and beyond. In a re-
view of bariatric literature by Puzziferri et al., to iden-
tify studies that had 80 % or greater follow-up at
2 years and beyond, < 3 % of studies (29/1136) met
this inclusion criterion. Not all studies reported ad-
equate weight loss data or outcome data on diabetes,
hypertension, and dyslipidemia [61]. The authors state
that the estimates of the treatment effect are very
likely biased (overestimated) due to missing weight
loss and other outcome data on representative sam-
ples. It is suggested that bariatric studies use more
rigorous methods of patient engagement and reten-
tion in order to mitigate loss to follow-up [61].
The Newfoundland and Labrador Bariatric Surgery Cohort
(BaSCo) study
Study objective The objective of the current study is to
examine short- to mid-term outcomes (2–4 years) asso-
ciated with LSG. Eligible patients who have undergone
LSG will be followed during and after surgery to assess
health and other outcomes. Specific study objectives are
to examine:
1. 30-day complication rate and mortality, and long-term
complications (e.g., gastroesophageal reflux,
micronutrient deficiencies).
2. reduction in weight and/or body mass index (BMI),
including predictors of successful weight loss.
3. improvement or resolution of co‐morbid conditions
(i.e. diabetes, hypertension, dyslipidemia, NAFLD,
PCOS).
4. changes in prescription and over-the-counter
medication use.
5. improvement in measures of health‐related quality
of life and
6. the economic consequences associated with LSG
(e.g., direct costs and indirect costs).
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complications, a marked reduction in weight, improve-
ment/resolution of comorbid conditions, a reduction in
obesity-related medications, an improvement in quality
of life, and a decrease in direct healthcare and indirect
costs compared to pre-surgery costs.
Methods/Design
Study design
This is a prospective cohort study examining the effect-
iveness of LSG on patient health outcomes.
Study population
Setting
The Provincial Bariatric Surgery Clinic is located in
Eastern Health (EH). EH is the largest of four regional
integrated health authorities in Newfoundland and
Labrador (NL) and provides a full continuum of health
services to a regional population of more than 300,000.
It is also responsible for a number of unique provincial
programs, for example, the Provincial Bariatric Surgery
Clinic. The Provincial Bariatric Surgery Clinic was
established in May 2011. This multidisciplinary team
consists of three surgeons trained in bariatric surgery, a
nurse practitioner, and other allied health professionals.
Potential patients are most often referred via their
primary care provider to the clinic and are invited to
attend a pre-surgical education session. After the ses-
sion, interested patients meet with the bariatric nurse
practitioner where a detailed medical history is taken.
Patients then meet with a bariatric surgeon, and if
deemed to be a surgical candidate, they sign consent to
undergo bariatric surgery, specifically LSG. At the time
the team was developed, LSG was the only bariatric
procedure offered to eligible patients in the province.
Patient selection criteria for bariatric surgery
The eligible population consists of all patients who (1)
meet the Canadian Practice Guidelines criteria for the
surgical treatment of obesity (BMI ≥35 with risk factors,
or BMI ≥ 40) [3], (2) are referred by their primary care
provider to the bariatric team using a standardized refer-
ral form submitted to a central intake system, and (3)
receive preliminary eligibility screening by the nurse
practitioner. Following mandatory attendance at a pre-
surgical bariatric surgery general orientation and an
education session provided either face-to-face or via
webinar, patients are required to undergo an extensive
pre-operative work-up which includes a 2-week diet
trial (i.e.,1 week full-fluid diet and 1 week healthy eat-
ing) as well as a food journaling activity. All patients
meet one-on-one or via Telehealth with the nurse prac-
titioner for further assessment including a detailed
review of their weight history and past weight lossattempts, blood work and a sleep study to identify and
treat any sleep disordered breathing, as necessary. If
any other medical concerns are identified, patients are
consulted to the appropriate specialist (e.g., cardiolo-
gist, endocrinologist, respirologist) based on their co-
morbid condition. An appointment with one of the
three bariatric surgeons in the bariatric surgery clinic is
arranged to obtain formal surgical consent.
Inclusion criteria
 Male or female patients between 19 and 70 years of
age
 BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with significant
obesity-related comorbidities
 Maximum BMI 60 kg/m2 as per NL Bariatric
Surgery Program guidelines
 Attempted nonsurgical weight loss in the past
 Deemed medically, psychologically, and emotionally
stable to consent to surgery and partake in a diet
and lifestyle modification regime
Exclusion criteria
 Pregnant
Recruitment for bariatric surgery study
Once deemed eligible for surgery, a research nurse
coordinator approaches every patient to discuss potential
interest in the study. The research nurse gives each
eligible participant a brief explanation of the study, an
introductory letter addressed from the researcher, an
information sheet, and consent form, and asks if she can
contact them to discuss the research project in greater
detail after the potential participant has had 24 to 48 h
to review the materials. If agreeable to this request, the
research nurse calls or makes contact with the potential
participant at the bariatric surgery clinic or by telephone
to answer any questions and set-up a time during the
next visit to the clinic to obtain written consent and
complete baseline data collection. The study protocol is
illustrated in Fig. 1.
Surgical intervention
The surgical intervention is performed laparoscopically
under general anesthesia. A 6 port technique is per-
formed. The vascular supply of the stomach is divided
along the greater curve, starting 5 cm proximal to the
pylorus and up to the angel of His. A gastric sleeve is
created using multiple applications of a 60 mm linear
stapler after the sleeve size is calibrated using a 42Fr
bougie. The gastric specimen is removed via the left
upper quadrant port site. An endoscopic air leak test is
routinely done to confirm an intact staple line, and an
Fig. 1 The NL Bariatric Surgery Cohort Study: Patient Flow
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the first postoperative day before the introduction of oral
liquid diet. If this is clear, patients are started on a clear
liquid diet and are normally discharged home on post-
operative day two with dietary instructions.Data collection
Patients are followed by the provincial bariatric surgery
clinic team as standard of care. The patients are assessed
by a bariatric surgeon 6–8 weeks post-surgery. In‐person
follow-up visits or assessments via Tele-health with theNurse Practitioner/bariatric care team take place at 1, 3,
6, 12, 18, and 24 months, and annually thereafter.
Study measures
Standardized case report forms (SCRFs) developed in
collaboration with Eastern Health and in consultation
with other Canadian bariatric programs are used to col-
lect relevant research and clinical data. Clinical data
such as weight measures and blood work are collected
by the clinical team (the nurse practitioner) and pro-
vided to the research team via a research nurse. The re-
search nurse collects data on individual patients at each
follow‐up visit using the SCRFs (Table 1).
Evaluation of health care utilization and costs
The impact of bariatric surgery on the health system will
be examined by comparing health care use and costs
(e.g., physician visits, hospitalizations, medications and
associated costs) 3 years pre‐and 2 years post‐surgery
(Table 2). In NL, the Centre for Health Information
(NLCHI) maintains a number of key health-related data
sources on behalf of the provincial Ministry of Health.
These databases comprehensively capture patient-
specific health care resource utilization. These include
vital statistics (mortality) and validated, high quality,
detailed measurement of the following health care
resources and costs: inpatient and outpatient encoun-
ters, physician billings, diagnostic tests, procedures, and
long-term care use. In addition to providing detailed
information allowing patient-specific costing of each
encounter, inpatient databases record diagnostic and
procedural information using the ICD-10-CA and CCI
classification systems [62]. Using unique provincial
health insurance numbers, the NLCHI will link the
bariatric clinical/research data with administrative health
services data and provide the research team with a de‐
identified database of health services use and costs for
data analysis purposes [63, 64].
Outcomes
Primary outcome: weight loss
Absolute (kg, BMI) changes and percent changes
(%EWL, %TWL, % change in BMI) from baseline will be
reported. Percent Excess Weight Loss (%EWL) is calcu-
lated as100% x ([W0 – W1]/EW0) where W0 is the
weight (kg) at the time of the surgery, W1 is the weight
(kg) at the last follow‐up and EW0 is the excess weight
at the time of the surgery, based on ideal weights found
in the Metropolitan tables for middle frame individuals
[65]. Percent Total Weight Loss (%TWL) is calculated as
100 % x ([W0-W1]/W0) where W0 is the weight (kg) at
the time of the surgery, W1 is the weight (kg) at the last
follow‐up. Using definitions of successful weight loss
12 months after bariatric surgery, we will calculate the
Table 1 Study measures and data collection time periods
Study Measures Source Variable Time frame (s)
Socio-demographics/Lifestyle Patient
Interview
Age, sex, ethnicity, current marital status, highest level
of education, occupation, current employment status,






Weight1, height2, BMI3 Pre-surgery, 3, 6, 12, 18,








sleep apnea, NAFLD, PCOS, etc.
Pre-surgery
Assessment of obesity-related
comorbid conditions to evaluate




Diabetes, hypertension, dyslipidemia, NAFLD, PCOS 3, 6, 12, 18, 24 months
and annually thereafter
PCOS will be assessed
at 12 months only
Medication use Standardized
Case Report Form
Prescribed and over-the-counter medications
(name, type, dosage, frequency and duration)
Pre-surgery, 3, 6, 12, 18,




Blood pressure4, heart rate Pre-surgery, 3, 6, 12, 18,





HbA1c, fasting blood glucose, insulin level, creatinine, fasting
lipid panel (including total cholesterol, LDL, HDL, triglycerides),
high sensitivity (hs) CRP, GGT, albumin, total bilirubin, ALP,
ALT, total protein, ferritin, hemoglobin, MCV, TSH, 25-OH D,
Vitamin B12
Pre-surgery, 3, 6, 12, 18,
24 months and annually
thereafter
Health-related QoL Validated surveys SF 12v2, EQ‐5D, IWQoL‐Lite Pre-surgery, 6, 12, 18,
24 months
Operative data Clinical database and
chart review
Minor and major complications During surgery and up to
30 days post-surgery
1Body weight is measured using a validated, calibrated bariatric scale and recorded to the nearest 0.1 kg, with the subject wearing light indoor clothing with
empty pockets, no shoes, and an empty bladder
2Height is measured to the nearest 0.1 cm using a wall-mounted stadiometer
3BMI = weight in kg/height in m2
4A single reading taking using an automated blood pressure monitor and using an appropriately sized blood pressure cuff will be recorded with the subject
seated in a chair and after 5 min of rest
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addition, the proportion of subjects that achieve
clinically important weight loss (i.e. ≥ 5 and 10 %)
will be reported [3].
Sample size calculation
The primary outcome for the sample size determination
was defined as successful weight loss at 12 months after
bariatric surgery. This was calculated as percentage of
patients who attain (>50 % EWL) at 12 months post-
surgery. Sample size was estimated using an online
calculator for population surveys as follows: n = (Z2 × P
(1 – P))/E2 where Z = value from standard normal
distribution corresponding to desired confidence level
(Z = 1.28 for 80 % CI), P is expected true proportion
and E is desired precision (half desired CI width). As-
suming that 50–60 % of patients undergoing LSG will
achieve the primary outcome of weight loss (>50 %
EWL), a total of 165 patients will be required for a pre-
cision of ±5 % at a confidence level of 80 %. To accountfor missing information from some patients, the sample
size has been inflated to 200.
Secondary outcomes
1. Complications of surgery
30-day complication rate and mortality will be
reported. Longer-term complications such as
gastroesophageal reflux and micronutrient
deficiencies will be examined. To examine
micronutrient deficiencies, the following
biochemical parameters associated with
micronutrients will be assessed (25-hydroxyvitamin
D (25-OH-D), parathyroid hormone (PTH),
calcium, vitamin B12, ferritin, mean cell volume
(MCV) and hemoglobin). The analysis for 25-OH-D
used liquid chromatography coupled with tandem
mass spectrometry. Hemoglobin and MCV were
analyzed on the Beckman Coulter®HMX Hematology
Analyzer, while ferritin, vitamin B12, and intact PTH
Table 2 Short to mid-term health care use and costs in surgical patients





1. Inpatient encounters # of hospitalizations (acute care)
Length-of-stay (LOS)
Newfoundland and Labrador Centre
for Health Information (NLCHI) Clinical
Database Management System (CDMS),
based on the Discharge Abstract Database
(DAD) includes LOS, procedures performed,
associated diagnoses, RIW and complexity
values
NLCHI/Canadian Institute for Health
Information (CIHI) methodology to
cost acute care encounters using
resource-intensity-weights (RIW)
and complexity values
Provided by fiscal year.
Referenced to time zero
(date of surgery)
2. Outpatient encounters # encounters
# procedures
NLCHI CDMS (based on DAD) includes
surgical day care procedures
NLCHI/CIHI methodology to cost
surgical day care encounters
Provided by fiscal year.
Referenced to time zero
3. Physician Fees (Fee for Service) # of encounters
Provider specialty
Service provided
Medical Care Plan (MCP) Physician Claims MCP Physician Claims Provided by fiscal year.
Referenced to time zero
4. Physician Fees (self-report) # of encounters
Provider specialty
Service provided
Patient interview (standardized case
report form)
Estimated using MCP Physician Claims Information obtained every
6 months
5. Medications Name dosage, frequency & duration Patient interview (standardized case
report form)
NL Drug (Provincial Formulary) Information obtained every
6 months
6. Transfer Payments Unemployment insurance
Disability benefits
Patient interview (standardized case
report form)
Patient Reported Information obtained every
6 months
8. Employment status, absenteeism Employment status in past year
(# hours/week, # weeks)
Absenteeism in past year (# days)
Annual income (by quintile)
Patient interview (standardized
case report form)
Average wage rate by age, sex and
region from Statistics Canada
Information obtained every
6 months
9. Weight Loss Interventions Weight loss program, meal replacements,
physical trainer, exercise programs,
alternative therapies (Binary Y/N)
Patient interview (standardized
case report form)
Patient reported out of pocket cost




10. Mobility and Medical Mobility aids, home modification/renovations,
rehabilitation, paid personal assistance





Patient reported out of pocket
cost/co-payments for medical services




DAD Discharge Abstract Database, LOS Length of stay, CIHI Canadian Institute for Health Information, CDMS Clinical Database Management System, RIW Resource Intensity Weight, MCP Newfoundland and Labrador
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Diagnostics. Calcium was analyzed on the Architect c
System by Abbots Diagnostics.
2. Comorbid Condition Improvement/Resolution
Improvement in comorbid conditions (i.e.
hypertension and dyslipidemia) is defined as any
reduction in medication use or treatment.
Comorbidity resolution is defined as complete
cessation of treatment/medication.
For the comorbid conditions of prediabetes and type
2 diabetes mellitus, specific definitions of diagnosis
are used as outlined in the Canadian Diabetes
Association Clinical Practice Guidelines [66].
Prediabetes is defined as fasting plasma glucose
(FPG) levels of 6.1–6.9 mmol/L and/or glycated
hemoglobin (A1C) levels of 6.0–6.4 % [66]. Type 2
diabetes mellitus is defined as FPG ≥ 7.0 mmol/L
and/or A1C ≥ 6.5 % [66].
Additional criteria will used to assess improvement
and resolution of prediabetes and diabetes [67].
Case definitions of improvement and remission of
prediabetes will be as follows: Improvement will be
based on achievement of the following: (1) lower
glycemic measures (2) at least 1 year’s duration, and
(3) pharmacologic therapy required but at a lower
dose. Normalization is defined as (1) normal
glycemic measures (2) at least 1 year’s duration, and
(3) pharmacologic therapy required but at a lower
dose. Remission is based on (1) normal glycemic
measures (2) at least 1 year’s duration, and (3) no
active pharmacologic therapy. Case definitions of
improvement and remission of Type 2 diabetes
mellitus [67] will be defined as follows.
Improvement will be based (1) hyperglycemia below
diagnostic thresholds for T2DM (2) at least 1 year’s
duration, and (3) pharmacologic therapy required
but at a lower dose. Partial remission is based on
the following (1) hyperglycemia below diagnostic
thresholds for T2DM (2) at least 1 year’s duration,
and (3) no active pharmacologic therapy. Complete
remission is based on the following criteria (1)
normal glycemic measures (2) at least 1 year’s
duration, and (3) no active pharmacologic therapy.
The status of specific biochemical parameters
associated with NAFLD prior to and following LSG
will be assessed using the following markers: total
bilirubin, alanine phosphatase (ALP), alanine
transaminase (ALT), gamma glutamyl transpeptidase
(GGT), high-density lipoprotein (HDL), low-density
lipoprotein (LDL), and triglycerides. Biochemical
parameters associated with NAFLD were analyzed
on the Architect c System by Abbots Diagnostics.
The prevalence of PCOS will be determined prior to
surgery based on self-report while changes in related(e.g., period frequency and regularity, menstrual flow
and intensity, hirsutism, acne, fertility, post-surgery
conception) and metabolic symptoms (insulin
sensitivity, T2DM, dyslipidemia, hypertension) will
be examined 1-year after LSG.
3. Change in medication use
Changes in prescription and over-the-counter
medication use and associated costs will be examined
including total number of medications and changes
(dose changes, medication discontinuations, and
initiation of additional medications) by disease
indication.
4. Quality of Life
Health related quality of life is assessed using
validated instruments. Generic and disease-specific
instruments will be used. All participants will
complete the Short Form (SF)-12, Euroqol (EQ)-5D,
and the Impact of Weight on Quality of Life
(IWQOL)-Lite pre-surgery at 6, 12, 18, and
24 months after surgery. The SF-12 (Version 2) is a
condensed 12-question version of the SF-36 [68]. It
yields a physical and a mental health component
summary score. Three-to-five point difference in
either score are considered clinically meaningful
[69, 70]. The EQ-5D is an indirect preference-based
health survey that consists of a 5 dimension
descriptive system [71] and an overall health visual
analog scale (EQ- VAS). A 0.03 point difference in
EQ-5D index score and 10 point difference on the
EQ-VAS are considered clinically meaningful [72].
The IWQOL-Lite is a short form of the IWQOL
and is the first instrument specifically developed to
assess the effects of obesity on the quality of life of
persons who are seeking weight loss treatment [73].
The IWQOL-lite consists of 31 items that describe
5 domains of obesity-specific HRQL. A difference
in the total score of 7–12 points for IWQOL-Lite is
considered clinically meaningful [74].
5. Economic consequences of bariatric surgery
Direct healthcare use/costs (e.g., hospitalizations,
physician visits, medication use) and indirect costs
(e.g., cost of weight loss interventions, employment
and absenteeism, home productivity, transfer
payments) will be compared 3 years prior to surgery
and 2 years post- surgery in order to determine the
economic consequences of bariatric surgery.
Data analysis
Non-identifying patient information obtained from the
standardized case report forms used to collect patient
information at baseline, administrative records and med-
ical chart reviews were entered into a Statistical Package
for Social Sciences database. All statistical analyses will
be performed using IBM SPSS Statistics for Windows,
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demographic details of patients pre-surgery and clinical
information collected at the time of surgery. In each
analysis to be conducted to address the six main re-
search objectives for this program, categorical variables
(such as 30-day complication rate and mortality; and
long-term complications e.g., gastro esophageal reflux,
micronutrient deficiencies) will be presented as
frequencies and chi-square tests conducted to identify
differences in pre–post surgical outcomes. Continuous
variables with a normal distribution will be reported as
means ± SD. Variables with a non-normal distribution
will be reported as medians and interquartile ranges. For
example, health services use such as number of physician
visits often has a non‐normal distribution; therefore me-
dian and quartiles will be reported when comparing use
pre‐ and post‐surgery. The Analysis of Variance (ANOVA)
or the paired t-method will be used to assess differ-
ences in continuous outcome pre and post-surgery.
Pairwise-comparison of pre with post-surgical patients’
outcomes at 3, 6, 12, 18 and 24 months will be done
using matched t-tests for continuous outcomes such as
BMI. Regression analyses methods will be performed
to identify independent predictors of outcomes of
interest (i.e., reduction in weight and/or BMI, includ-
ing predictors of successful weight loss; improvement
or resolution of co‐morbid conditions (i.e., diabetes,
hypertension, dyslipidemia, NAFLD, PCOS); changes
in prescription and over-the-counter medication use;
improvement in measures of health‐related quality of life.
For continues outcomes, mean differences, standard
errors, 95 % confidence intervals and p-values will be pre-
sented. For categorical outcomes, odds ratios and 95 %
confidence intervals will be presented. Generalized esti-
mating equations with binary logistic regression will be
used for all response or outcome events to take into
account the correlations between repeated measures post-
surgery providing an estimated adjusted odds ratio and
95 % confidence intervals. Statistical significance is set at
p < 0.05.
To examine the predictors of change in patient’s
2 years post-surgery, MIXED modelling regression
approach [76, 77] implemented in SPSS will be used to
assess baseline patient’s factors that determine individual
changes in individual maintaining weight loss over the
24 months. The mixed modeling approach will also
allow us to take into account the correlations between
repeated measures and accounts for missing data over
time. Statistical significance effect of factors producing
changes or reduction in weight and/or BMI, including
predictors of successful weight loss overtime in the
24 month post-surgery would be set at p < 0.05. Cost-
effectiveness will be performed to evaluate the economic
consequences associated with LSG. The economicanalyses will be carried out on a per protocol basis and
would be based on patients for whom there was
complete resource use and health outcome data pro-
vided by the NL Centre for Health Information.
Ethics and privacy
We have received full ethics approval for the NL Bariat-
ric Surgery Study [Health Research Ethics Authority
(HREA) 11.101]. Patient informed consent was obtained
and subjects were informed they could withdraw from
the study at any time. The research nurse is the only
member of the team who has access to identifying pa-
tient information. This information is kept in a locked
cabinet in a secure office. De-identified data is secured
in password protected files and only accessed by re-
searchers involved in the study for the purpose of data
analysis. As with previous projects involving the compil-
ation of sensitive datasets from multiple sources such as
cancer registries and physician billings, the protection of
individual privacy and anonymity and confidentiality will
be maintained by having NLCHI act as a trusted third
party.
Discussion
In summary, the demand for LSG as a stand-alone pro-
cedure is growing in popularity as a treatment for class
II and III obesity. In a joint report “Developing a
Research Agenda to Support Bariatric Care” published
by the CIHR and the Canadian Obesity Network in
2010, the gaps in research related to bariatric surgery
were highlighted [78]. Although LSG was not specifically
highlighted in the report, compared to other bariatric
surgeries, research on LSG as a treatment for severe
obesity is limited due to its relatively recent provision as
a stand-alone procedure. The start-up of a bariatric sur-
gery program offering LSG as a treatment for severe
obesity combined with the limited research on LSG pro-
vided an opportunity for research. Consequently, an
Integrated Knowledge Translation Team was established at
Memorial University, comprised of academic researchers,
healthcare professionals, decision-makers, and policy
makers, and a program of research on bariatric care was
developed to address key gaps in the research literature.
One of the studies designed and implemented within this
program of research and presented in this paper is a quasi-
experimental study that aims to address current knowledge
gaps in LSG by generating prospective, population-based
Canadian outcome data. This study is being conducted in a
provincial bariatric surgery program within a tertiary care
teaching centre and the results will be generalizable to
similar programs offering bariatric surgery. A current re-
view continues to highlight a major concern previously
identified by others [79, 80] associated with bariatric sur-
gery as a treatment for obesity. It is not the magnitude of
Twells et al. BMC Health Services Research  (2016) 16:618 Page 11 of 13initial weight loss which has been well documented but the
mid- to long-term sustainability of weight loss that is under
question. Very few bariatric studies report long-term
results with sufficient patient follow-up (>80 %) in order to
minimize biased results. In addition, insufficient evidence
exists regarding long-term outcomes for LSG [61]. In
response to this concern and as part of the current study
protocol, a clinical database to house all program data in
order to monitor longer-term (>5 years) patient health out-
comes has been developed which will also allow for data
linkages with administrative data to examine health care
use and costs in the future. Further interventions being
used in order to decrease attrition and increase patient en-
gagement include the use of technology (e.g., Tele-health
and webinar sessions for educational purposes). As of
August 2015, 100 % recruitment has been achieved with
completion of follow-up to be completed by September
2016 with study results to be published in late 2016 and
early 2017. Our study population is 82 % female, with an
average age, weight, and BMI of 44 years, 135 kgs and
49 kg/m2, respectively. The prevalence rates of hyperten-
sion and dyslipidemia were approximately 50 and 43 % had
T2DM. Our study participants are similar to other patient
populations that are eligible for and undergoing bariat-
ric surgery elsewhere in Canada [15, 21], increasing the
external validity of our study findings.
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